Further, TGII values for GC1118 and cetuximab in CRC-034T (KRAS G12V; high-affinity ligand expression, 72.2%; low-affinity, 27.8%) were 34.5% (p = 0.023) and 103.6% (p = 0.12), respectively (GC1118 vs. cetuximab, p = 0.019; Figure 3A, lower panel and Table S2). This evidence concerns the gene KRAS and colorectal carcinoma.